ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NATR vs BBOT // EV/EBITDA & P/E VALUATION

Nature's Sunshine Products Inc. (NASDAQ) VS. BridgeBio Oncology Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NATR 3 — BBOT 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NATR VS. BBOT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NATR BBOT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 72.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 28.90% -35.00% +63.90 NATR /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 4.0x — — TIE /valuation <GO>
Free Cash Flow Yield 13.35% — — TIE /fcf-yield <GO>
Operating Margin 5.20% — — TIE /operating-margins <GO>
Net Profit Margin 4.10% — — TIE /net-margins <GO>
Revenue Growth (YoY) 5.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 4.33 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 2/9 +6.00 NATR /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.8 24.1 +17.71 NATR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 10.3x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $216.1M $216.5M -$397.5K BBOT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NATR REV BBOT REV NATR GROSS % BBOT GROSS % NATR FCF BBOT FCF
FY 2025 $480.1M $0 72.4% — $28.8M -$114.5M
FY 2024 $454.4M $0 71.5% — $14.3M -$55.1M
FY 2023 $445.3M $0 — — $41.2M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NATR // BETA —
BBOT // BETA —